Veerle d’Haenens

Veerle d’Haenens

General Manager, Global Therapy Innovations

As head of the Global Therapy Innovations business units, Veerle leads cross-functional teams transforming business models and solutions to meet the changing needs of our global customers and patients. This includes translating strategy into practical approaches to reach more patients with our products and capturing real-time insights for a diverse and comprehensive portfolio.

To bring the right therapies at the right time in the patient’s treatment journey, Veerle’s focus is leveraging unique synergies and strengths across the portfolio and services to help increase patient access to care. She and her teams are shaping the cell therapy ecosystem to better facilitate the journey of lifesaving cells from patient and donor cell collections through cell processing and manufacturing, a holistic approach to help make innovative therapies accessible to more patients. At the same time, they will continue to enhance the therapeutic potential and future development of the company’s industry-leading Spectra Optia^™ Apheresis System.

Veerle’s interest in healthcare comes from her passion to make a meaningful contribution to society. She believes that working with a diverse, engaged team behind clearly defined goals drives results that enable more patients to get access to healthcare and better treatment options.

She has worked in healthcare for more than 20 years, across the pharmaceutical and medical device sectors in a variety of commercial and marketing leadership roles. With this experience and perspective, she inspires and mobilizes people and teams around a clear vision and strategy.

Veerle previously served as Vice President, Commercial, Europe, Middle East, Africa (EMEA). She was also the Commercialization Director for EMEA Therapeutic Systems, where she successfully repositioned the business across Europe as a partner to provide clinical solutions and disease therapies. She joined the company in 2010 as a Sales Manager.

Before joining Terumo Blood and Cell Technologies, she worked at Pfizer in various business units, most recently as the Business Unit Director, Rheumatology and Dermatology.

Veerle graduated with distinction from the University of Leuven. Her engineering degree focused on a specialization for chemical and agriculture industries, including industrial biology and microbiology, as well as cell and gene technology